Abstract
Evodiamine, a major component of Evodia rutaecarpa, has been reported to possess various pharmacological activities, including anti-inflammatory, antioxidative stress, and neuroprotective effects. Our previous study has shown that the potential effects of evodiamine on the learning and memory impairments in the transgenic mouse model of Alzheimer’s disease (AD). The present study was designed to investigate neuroprotective mechanism and therapeutic potential of evodiamine against intracerebroventricular streptozotocin (ICV-STZ)-induced experimental sporadic Alzheimer’s disease in mice. STZ was injected twice intracerebroventrically (3 mg/kg ICV) on alternate days (day 1 and day 3) in mice. Daily oral administration with evodiamine (50 or 100 mg/kg per day) starting from the first dose of STZ for 21 days showed an improvement in STZ induced cognitive deficits as assessed by novel object recognition and Morris water maze test. Evodiamine significantly decreased STZ induced elevation in acetylcholinesterase activity and malondialdehyde level, and significantly increased STZ induced reduction in glutathione activities and superoxide dismutase activities in the hippocampus compared to control. Furthermore, evodiamine inhibited significantly glial cell activation and neuroinflammation (TNF-α, IL-1β, and IL-6 levels) in the hippocampus. Moreover, evodiamine increased the activity of AKT/GSK-3β signalling pathway and inhibited the activity of nuclear factor κB. In summary, our study suggests that evodiamine can be a novel therapeutic agent for the management of sporadic AD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- Ache:
-
Acetylcholinesterase
- AD:
-
Alzheimer’s disease
- APP:
-
Amyloid precursor protein
- ACSF:
-
Artificial cerebral spinal fluid
- fAD:
-
Familial Alzheimer’s disease
- GSH:
-
Glutathione
- ICV:
-
Intracerebroventricular
- MDA:
-
Malondialdehyde
- NF-κB:
-
Nuclear factor κB
- Evo:
-
Evodiamine
- sAD:
-
Sporadic Alzheimer’s disease
- STZ:
-
Streptozotocin
- SOD:
-
Superoxide dismutase
References
Bevins RA, Besheer J (2006) Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study ‘recognition memory’. Nat Protoc 1:1306–1311. https://doi.org/10.1038/nprot.2006.205
Blokland A, Jolles J (1993) Spatial learning deficit and reduced hippocampal ChAT activity in rats after an ICV injection of streptozotocin. Pharmacol Biochem Behav 44:491–494
Chang CP, Chang JY, Wang FY, Tseng J, Chang JG (1995) The effect of Evodia rutaecarpa extract on cytokine secretion by human mononuclear cells in vitro. Am J Chin Med 23:173–180. https://doi.org/10.1142/S0192415X95000237
Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi KL (2009) Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine—a PDE1 inhibitor. Eur J Pharmacol 620:49–56. https://doi.org/10.1016/j.ejphar.2009.08.027
Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, Hammers A, Tai YF, Fox N, Kennedy A, Rossor M, Brooks DJ (2008) Microglia, amyloid, and cognition in Alzheimer’s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 32:412–419. https://doi.org/10.1016/j.nbd.2008.08.001
Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM (2016) Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol 14:101–115
Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137–147
Ghosh A, Chen F, Wu F, Tang SS, Hu M, Long Y, Sun HB, Kong LY, Hong H (2017) CysLT1R downregulation reverses intracerebroventricular streptozotocin-induced memory impairment via modulation of neuroinflammation in mice. Prog Neuropsychopharmacol Biol Psychiatry 73:19–30. https://doi.org/10.1016/j.pnpbp.2016.10.001
Grieb P (2016) Intracerebroventricular streptozotocin injections as a model of Alzheimer’s disease: in search of a relevant mechanism. Mol Neurobiol 53:1741–1752. https://doi.org/10.1007/s12035-015-9132-3
Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101:757–770. https://doi.org/10.1111/j.1471-4159.2006.04368.x
Gutierres JM, Carvalho FB, Schetinger MR, Marisco P, Agostinho P, Rodrigues M et al (2014) Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer’s type. Life Sci 96:7–17. https://doi.org/10.1016/j.lfs.2013.11.014
Heneka MT, O’Banion MK (2007) Inflammatory processes in Alzheimer’s disease. J Neuroimmunol 184:69–91. https://doi.org/10.1016/j.jneuroim.2006.11.017
Ifuku M, Katafuchi T, Mawatari S, Noda M, Miake K, Sugiyama M, Fujino T (2012) Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice. J Neuroinflammation 9:197. https://doi.org/10.1186/1742-2094-9-197
Javed H, Khan MM, Khan A, Vaibhav K, Ahmad A, Khuwaja G, Ahmed ME, Raza SS, Ashafaq M, Tabassum R, Siddiqui MS, El-Agnaf OM, Safhi MM, Islam F (2011) S-allyl cysteine attenuates oxidative stress associated cognitive impairment and neurodegeneration in mouse model of streptozotocin-induced experimental dementia of Alzheimer’s type. Brain Res 1389:133–142. https://doi.org/10.1016/j.brainres.2011.02.072
Javed H, Vaibhav K, Ahmed ME, Khan A, Tabassum R, Islam F, Safhi MM (2015) Effect of hesperidin on neurobehavioral, neuroinflammation, oxidative stress and lipid alteration in intracerebroventricular streptozotocin induced cognitive impairment in mice. J Neurol Sci 348:51–59. https://doi.org/10.1016/j.jns.2014.10.044
Jiang ML, Zhang ZX, Li YZ, Wang XH, Yan W, Gong GQ (2015) Antidepressant-like effect of evodiamine on chronic unpredictable mild stress rats. Neurosci Lett 588:154–158. https://doi.org/10.1016/j.neulet.2014.12.038
Kamat PK, Tota S, Rai S, Swarnkar S, Shukla R, Nath C (2012) A study on neuroinflammatory marker in brain areas of okadaic acid (ICV) induced memory impaired rats. Life Sci 90:713–720. https://doi.org/10.1016/j.lfs.2012.03.012
Kim YE, Hwang CJ, Lee HP, Kim CS, Son DJ, Ham YW, Hellstrom M, Han SB, Kim HS, Park EK, Hong JT (2017) Inhibitory effect of punicalagin on lipopolysaccharide-induced neuroinflammation, oxidative stress and memory impairment via inhibition of nuclear factor-kappaB. Neuropharmacology 117:21–32. https://doi.org/10.1016/j.neuropharm.2017.01.025
Laczo J, Vlcek K, Vyhnalek M, Vajnerova O, Ort M, Holmerova I, Tolar M, Andel R, Bojar M, Hort J (2009) Spatial navigation testing discriminates two types of amnestic mild cognitive impairment. Behav Brain Res 202:252–259. https://doi.org/10.1016/j.bbr.2009.03.041
Lannert H, Hoyer S (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112:1199–1208
Liang KC, Hon W, Tyan YM, Liao WL (1994) Involvement of hippocampal NMDA and AMPA receptors in acquisition, formation and retrieval of spatial memory in the Morris water maze. Chin J Physiol 37:201–212
Liu Y, Zhang XJ, Yang CH, Fan HG (2009) Oxymatrine protects rat brains against permanent focal ischemia and downregulates NF-kappaB expression. Brain Res 1268:174–180. https://doi.org/10.1016/j.brainres.2009.02.069
Liu C, Wu Y, Zha S, Liu M, Wang Y, Yang G, Ma K, Fei Y, Zhang Y, Hu X, Yang W, Qian Y (2016a) Treatment effects of tanshinone IIA against intracerebroventricular streptozotocin induced memory deficits in mice. Brain Res 1631:137–146. https://doi.org/10.1016/j.brainres.2015.11.040
Liu Z, Chen HQ, Huang Y, Qiu YH, Peng YP (2016b) Transforming growth factor-beta1 acts via TbetaR-I on microglia to protect against MPP(+)-induced dopaminergic neuronal loss. Brain Behav Immun 51:131–143. https://doi.org/10.1016/j.bbi.2015.08.006
Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, Zhang M, Yang Y, Cai F, Woodgett J, Song W (2013) Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Investig 123:224–235. https://doi.org/10.1172/JCI64516
Mrak RE, Griffin WS (2001) Interleukin-1, neuroinflammation, and Alzheimer’s disease. Neurobiol Aging 22:903–908
Pathan AR, Viswanad B, Sonkusare SK, Ramarao P (2006) Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci 79:2209–2216. https://doi.org/10.1016/j.lfs.2006.07.018
Perry RT, Collins JS, Wiener H, Acton R, Go RC (2001) The role of TNF and its receptors in Alzheimer’s disease. Neurobiol Aging 22:873–883
Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–344. https://doi.org/10.1056/NEJMra0909142
Rai S, Kamat PK, Nath C, Shukla R (2014) Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats. Pharmacol Biochem Behav 117:104–117. https://doi.org/10.1016/j.pbb.2013.11.035
Rasul A, Yu B, Zhong L, Khan M, Yang H, Ma T (2012) Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy. Oncol Rep 27:1481–1487. https://doi.org/10.3892/or.2012.1694
Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659–661. https://doi.org/10.1096/fj.07-9574LSF
Salkovic-Petrisic M, Osmanovic-Barilar J, Bruckner MK, Hoyer S, Arendt T, Riederer P (2011) Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer’s disease: a long-term follow up study. J Neural Transm (Vienna) 118:765–772. https://doi.org/10.1007/s00702-011-0651-4
Santos DB, Colle D, Moreira EL, Peres KC, Ribeiro RP, dos Santos AA, de Oliveira J, Hort MA, de Bem AF, Farina M (2015) Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice. Neuroscience 284:590–600. https://doi.org/10.1016/j.neuroscience.2014.10.019
Schliebs R, Arendt T (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease. J Neural Transm (Vienna) 113:1625–1644. https://doi.org/10.1007/s00702-006-0579-2
Shi L, Yang F, Luo F, Liu Y, Zhang F, Zou M, Liu Q (2016) Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting beta-catenin-mediated angiogenesis. Tumour Biol 37:12791–12803. https://doi.org/10.1007/s13277-016-5251-3
Shoham S, Bejar C, Kovalev E, Weinstock M (2003) Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. Exp Neurol 184:1043–1052. https://doi.org/10.1016/j.expneurol.2003.08.015
Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, Savva G, Brayne C, Wharton SB (2010) Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging 31:578–590. https://doi.org/10.1016/j.neurobiolaging.2008.05.015
Sonkusare S, Srinivasan K, Kaul C, Ramarao P (2005) Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sci 77:1–14. https://doi.org/10.1016/j.lfs.2004.10.036
Steinbrecher KA, Wilson W III, Cogswell PC, Baldwin AS (2005) Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol Cell Biol 25:8444–8455. https://doi.org/10.1128/MCB.25.19.8444-8455.2005
Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB (2004) Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IκBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 279:39541–39554. https://doi.org/10.1074/jbc.M403449200
Takamura A, Okamoto Y, Kawarabayashi T, Yokoseki T, Shibata M, Mouri A, Nabeshima T, Sun H, Abe K, Urisu T, Yamamoto N, Shoji M, Yanagisawa K, Michikawa M, Matsubara E (2011) Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer’s disease model mouse. Mol Neurodegener 6:20. https://doi.org/10.1186/1750-1326-6-20
Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M (1999) Microglial activation resulting from CD40-CD40L interaction after β-amyloid stimulation. Science 286:2352–2355
Wei J, Ching LC, Zhao JF, Shyue SK, Lee HF, Kou YR, Lee TS (2013) Essential role of transient receptor potential vanilloid type 1 in evodiamine-mediated protection against atherosclerosis. Acta Physiol (Oxf) 207:299–307. https://doi.org/10.1111/apha.12005
Wu Y, Pan X, Xu Y, Lu X, He S, He R, Gong M (2016) Optimization of combinations of ginsenoside-Rg1, ginsenoside-Rb1, evodiamine and rutaecarpine for effective therapy of mouse migraine. J Nat Med 70:207–216. https://doi.org/10.1007/s11418-015-0960-2
Yin C, Deng Y, Gao J, Li X, Liu Y, Gong Q (2016) Icariside II, a novel phosphodiesterase-5 inhibitor, attenuates streptozotocin-induced cognitive deficits in rats. Neuroscience 328:69–79. https://doi.org/10.1016/j.neuroscience.2016.04.022
Yuan SM, Gao K, Wang DM, Quan XZ, Liu JN, Ma CM, Qin C, Zhang LF (2011) Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(DeltaE9) transgenic mouse models of Alzheimer’s disease. Acta Pharmacol Sin 32:295–302. https://doi.org/10.1038/aps.2010.230
Yuskaitis CJ, Jope RS (2009) Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 21:264–273. https://doi.org/10.1016/j.cellsig.2008.10.014
Zhao T, Zhang X, Zhao Y, Zhang L, Bai X, Zhang J, Zhao X, Chen L, Wang L, Cui L (2014) Pretreatment by evodiamine is neuroprotective in cerebral ischemia: up-regulated pAkt, pGSK3beta, down-regulated NF-kappaB expression, and ameliorated BBB permeability. Neurochem Res 39:1612–1620. https://doi.org/10.1007/s11064-014-1356-5
Zilka N, Ferencik M, Hulin I (2006) Neuroinflammation in Alzheimer’s disease: protector or promoter? Bratisl Lek Listy 107:374–383
Acknowledgements
The present work was supported by National Natural Science Foundation of China (81601225), the Young Backbone Teachers Assistance Scheme of Henan Province Colleges and Universities.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Wang, D., Wang, C., Liu, L. et al. Protective effects of evodiamine in experimental paradigm of Alzheimer’s disease. Cogn Neurodyn 12, 303–313 (2018). https://doi.org/10.1007/s11571-017-9471-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11571-017-9471-z